NEXI NexImmune Inc.

15.46
+0.5  (+3%)
Previous Close 14.96
Open 14.88
52 Week Low 10.1
52 Week High 28
Market Cap $349,828,988
Shares 22,628,007
Float 17,593,196
Enterprise Value $259,190,834
Volume 100,190
Av. Daily Volume 93,270
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
NEXI-002
Multiple Myeloma
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
NEXI-001
Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome (MDS) after allogeneic HCT
Phase 1/2
Phase 1/2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. GAITHERSBURG, Md., Sept. 10, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will participate in a fireside chat during the Morgan Stanley 19th Annual Global Healthcare Conference today, September 10, 2021 at 1:15p.m. Eastern time.

    The webcast will be accessible on the Investor Relations page of NexImmune's website at Events and Presentations | NexImmune, Inc. A replay of the presentation will be available at the same location for 30 days following the conference.

    About NexImmune

    NexImmune…

    GAITHERSBURG, Md., Sept. 10, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will participate in a fireside chat during the Morgan Stanley 19th Annual Global Healthcare Conference today, September 10, 2021 at 1:15p.m. Eastern time.

    The webcast will be accessible on the Investor Relations page of NexImmune's website at Events and Presentations | NexImmune, Inc. A replay of the presentation will be available at the same location for 30 days following the conference.

    About NexImmune

    NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune's approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.

    NexImmune's two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to at least 3 prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.

    For more information, visit www.neximmune.com.

    Contacts

    Investors:

    Chad Rubin, SVP Corporate Affairs

    NexImmune, Inc.

    646.319.3261

    crubin@neximmune.com 



    Primary Logo

    View Full Article Hide Full Article
    • Announcing first solid tumor indication in HPV associated-malignancies – NEXI-003
    • Advancing two lead product candidates in Phase 1/2 clinical trials
    • Additional clinical and preclinical data anticipated in the second half of 2021

    GAITHERSBURG, Md., Aug. 09, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported its financial results for the second quarter of 2021.

    "The first half of the year was a very productive period for the company. We are focused on completing enrollment in our Phase I/II clinical trials for NEXI-001 and NEXI-002 and expect to present additional clinical data for each during scientific conferences toward the end of this year," said Scott Carmer, Chief Executive Officer. "We are also excited to announce our first indication in solid tumors and expect to submit our IND for HPV-associated malignancies in the second quarter of 2022. Additionally, we've initiated IND-enabling pre-clinical experiments that will be the basis for multiple IND submissions in support of our injectable nanoparticle (AIM INJ). This progress highlights the promise of our AIM platform across disease areas and delivery modalities, and we look forward to providing further updates on these important programs later this year."

    Select 2Q 2021 Clinical and Business Highlights

    Clinical and Preclinical Updates

    NEXI-001

    • Abstract presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting in June 2021 highlights safety, tolerability, immune responses and early clinical activity in all patients evaluated
    • Dose Level 2 (single infusion of 200M cells/month x two cycles) is fully enrolled
    • Dose Level 3 (single infusion of 200M cells/week for three weeks x two cycles) is enrolling
    • Treatment-related adverse events, including infusion reactions, GVHD, CRS, and neurotoxicity (ICANS), have not been observed in patients who received NEXI-001 at Dose Level 1 and Dose Level 2, either as single or repeat infusions
    • Further data expected to be announced during the American Society of Hematology (ASH) Annual Meeting in December 2021

    NEXI-002

    • Abstract presented at European Hematology Association Annual Meeting in May 2021 highlights safety, tolerability and immune responses in all patients evaluated
    • Safety cohort completed and expansion phase is enrolling
    • Treatment-related adverse events, including infusion reactions, CRS, and neurotoxicity (ICANS), have not been observed in patients who received NEXI-002
    • Further data expected to be announced during the American Society of Hematology (ASH) Annual Meeting in December 2021

    NEXI-003

    • First solid tumor clinical trial for multi-antigen autologous AIM ACT product will target HPV-associated malignancies
    • Preclinical data validating the selection of multiple immunogenic HPV antigen peptides expected to be announced during the Society for Immunotherapy of Cancer's Annual Meeting (SITC 2021) in November 2021
    • Investigational new drug (IND) submission planned for 2Q 2022

    Other R&D

    • IND-enabling preclinical studies for the AIM INJ platform continue; abstract presentations planned for SITC 2021 in November 2021
    • First collaboration in autoimmune diseases announced with Yale University to evaluate AIM INJ nanoparticles in Type 1 diabetes

    Business Updates

    • Announced formation of the company's Scientific Advisory Board
    • Announced the appointments of Dr. Jack Ragheb, SVP, Translational Medicine, and Matthew Schiller, Head of Business Development

    Select 2Q 2021 Financial Highlights

    Cash, cash equivalents and marketable securities for the company as of June 30, 2021 were $102.8M compared to $118.1M for quarter ending March 31, 2021. Based upon current operating plans, NexImmune expects that its existing cash, cash equivalents and marketable securities will enable the company to fund its operating and capital expenditure requirements through the third quarter of 2022.

    Research and development expenses were $8.1M in the second quarter of 2021, compared to $4.2M for the same period in the prior year. The increase in R&D expenses was mainly attributable to costs for the two clinical trials, as well as personnel-related expenses driven by increased headcount.

    General and administrative expenses were $4.0M, compared to $2.6M for the same period the prior year. The increase was due primarily to increases in headcount and fees related to professional and consulting services.

    Net loss, according to generally accepted accounting principles in the U.S. (GAAP), was $12.2M for the quarter, or a basic and diluted GAAP loss per share of $0.54. This compared to a net loss of $6.9M, or a basic and diluted GAAP loss per share of $6.17, for the same period the prior year.

    About NexImmune

    NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune's approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.

    NexImmune's two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to 3 or more prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.

    For more information, visit www.neximmune.com.

    Forward Looking Statements

    This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NexImmune, Inc. (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning our results of operations for the six months ended June 30, 2021; the sufficiency of the Company's current cash, cash equivalents and marketable securities to fund its planned operations through the third quarter of 2022; our planned and ongoing clinical studies for the Company's product candidates, including NEXI-001, NEXI-002 and NEXI-003; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the utility of prior preclinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission ("SEC") on March 31, 2021, and subsequent reports that we file with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.



    NEXIMMUNE, INC.

    BALANCE SHEETS

       
     June 30,

    2021

     December 31,

    2020

     (unaudited)

      
    ASSETS  
    Current assets:  
    Cash and cash equivalents$63,816,106  $5,031,079 
    Marketable securities 38,979,670    
    Restricted cash 67,500   67,500 
    Prepaid expenses and other current assets 8,327,117   3,293,858 
    Total current assets 111,190,393   8,392,437 
    Property and equipment, net 4,148,875   2,885,260 
    Other non-current assets 53,373   23,373 
    Total assets$115,392,641  $11,301,070 
    LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)  
    Current liabilities:  
    Accounts payable$2,169,660  $2,760,129 
    Accrued expenses 2,469,942   2,603,027 
    Derivative liability    1,702,359 
    Other current liabilities 843,619   843,619 
    Convertible notes issued to related parties    7,324,267 
    Convertible notes    11,793,397 
    Total current liabilities 5,483,221   27,026,798 
    Deferred rent, net of current portion  23,529 
    Other non-current liabilities    4,935 
    Total liabilities 5,483,221   27,055,262 
    Commitments and contingencies  
    Redeemable convertible preferred stock  
    Series A Redeemable Convertible Preferred Stock, $0.0001 par value, no shares outstanding as of June 30, 2021 and 121,735,303 shares authorized, issued and outstanding as of December 31, 2020. Liquidation value of $42,314,789 as of December 31, 2020.    35,047,435 
    Series A-2 Redeemable Convertible Preferred Stock, $0.0001 par value, no shares outstanding as of June 30, 2021 and 28,384,899 shares authorized, 22,047,361 shares issued and outstanding as of December 31, 2020. Liquidation value of $8,683,746 as of December 31, 2020.    7,685,865 
    Series A-3 Redeemable Convertible Preferred Stock, $0.0001 par value, no shares outstanding as of June 30, 2021 and 34,061,879 shares authorized, 31,209,734 shares issued and outstanding as of December 31, 2020. Liquidation value of $11,699,176 as of December 31, 2020.    10,887,449 
    Total redeemable convertible preferred stock    53,620,749 
    Stockholders' equity (deficit)  
    Common Stock, $0.0001 par value, 250,000,000 shares authorized, 22,628,007 issued and outstanding as of June 30, 2021 and 1,256,609 shares issued and outstanding as of December 31, 2020. 2,263   126 
    Additional paid-in-capital 207,480,819   8,206,938 
    Accumulated other comprehensive loss (2,917)   
    Accumulated deficit (97,570,745)  (77,582,005)
    Total stockholders' equity (deficit) 109,909,420   (69,374,941)
    Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)$115,392,641  $11,301,070 
       



    NEXIMMUNE, INC.

    STATEMENTS OF OPERATIONS

    (unaudited)

          
      Three Months Ended

    June 30,


     Six Months Ended

    June 30,


       2021  2020  2021  2020
    Revenue $  $  $  $ 
    Operating expenses:     
    Research and development  8,124,973   4,209,261   14,137,581   8,481,428 
    General and administrative  4,038,050   2,565,402   8,095,642   4,653,803 
    Total operating expenses  12,163,023   6,774,663   22,233,223   13,135,231 
    Loss from operations  (12,163,023)  (6,774,663)  (22,233,223)  (13,135,231)
    Other (expense) income:     
    Interest income  6,851   1,184   10,464   19,868 
    Interest expense  (101)  (183,682)  (904,220)  (184,671)
    Change in fair value of derivative liability        2,424,877    
    Other (expense) income  (25,974)  26,636   (26,696)  54,001 
    Other (expense) income  (19,224)  (155,862)  1,504,425   (110,802)
    Net Loss $(12,182,247) $(6,930,525) $(20,728,798) $(13,246,033)
    Accumulated dividends on Redeemable Convertible Preferred Stock     (815,816)  (377,562) $(1,631,632)
    Net loss attributable to common stockholders $(12,182,247) $(7,746,341) $(21,106,360) $(14,877,665)
    Basic and diluted net loss attributable to common stockholders per common share $(0.54) $(6.17) $(1.20) $(11.86)
    Basic and diluted weighted-average number of common shares outstanding  22,608,866   1,254,681   17,648,551   1,254,681 
                     



    STATEMENTS OF COMPREHENSIVE LOSS


    (unaudited)

          
      Three Months Ended

    June 30,


     Six Months Ended

    June 30,


      2021 2020 2021 2020
    Net loss $(12,182,247) $(6,930,525) $(20,728,798) $(13,246,033)
    Other comprehensive loss:     
    Unrealized (loss) gain on available-for-sale marketable securities, net of tax  (2,917)     (2,917)  (506)
    Comprehensive loss $(12,185,164) $(6,930,525) $(20,731,715) $(13,246,539)
          

    Contacts

    Investors:

    Chad Rubin, SVP, Corporate Affairs

    NexImmune, Inc.

    646.319.3261

    crubin@neximmune.com

    Media:

    Mike Beyer

    Sam Brown Inc. Healthcare Communications

    312.961.2502

    mikebeyer@sambrown.com



    Primary Logo

    View Full Article Hide Full Article
  2. GAITHERSBURG, Md., Aug. 09, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a collaboration with Yale University's Department of Immunobiology. The collaboration will focus on the use of NexImmune's direct injection, artificial antigen presenting cells (AIM INJ) with regards to the regulation of autoimmune diabetes (Type 1 diabetes). Dr. Kevan Herold, Deputy Director of Yale Center for Clinical Investigation and Co-Director of the Yale Diabetes Center will be the principal investigator.

    "We are excited to enter into this collaboration…

    GAITHERSBURG, Md., Aug. 09, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a collaboration with Yale University's Department of Immunobiology. The collaboration will focus on the use of NexImmune's direct injection, artificial antigen presenting cells (AIM INJ) with regards to the regulation of autoimmune diabetes (Type 1 diabetes). Dr. Kevan Herold, Deputy Director of Yale Center for Clinical Investigation and Co-Director of the Yale Diabetes Center will be the principal investigator.

    "We are excited to enter into this collaboration that will explore our next-generation, direct-injectable artificial antigen presenting cell platform for autoimmune diseases," said Dr. Jerry Zeldis, Executive Vice President, R&D of NexImmune. "Our goal with Dr. Herold is to advance novel treatments that could potentially reverse the course and prevent type 1 diabetes by targeting the auto-reactive T cells that cause this disease."

    "By directly targeting the auto-reactive T cells that are known to be a mediator of pancreatic beta cell destruction, we can potentially develop a transformative therapy for patients suffering with autoimmune diabetes. Working with NexImmune allows us to explore a very compelling technology to impact this life-long and difficult to control disease," stated Dr. Herold.

    About NexImmune

    NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune's approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.

    NexImmune's two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to at least 3 prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.

    For more information, visit www.neximmune.com.

    Forward Looking Statements

    This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NexImmune, Inc. (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning our planned and ongoing clinical studies for the Company's product candidates, including NEXI-001 and NEXI-002; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the utility of prior preclinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission ("SEC") on March 31, 2021, and subsequent reports that we file with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    Contacts

    Investors:

    Chad Rubin, SVP, Corporate Affairs

    NexImmune, Inc.

    646.319.3261

    crubin@neximmune.com 



    Primary Logo

    View Full Article Hide Full Article
  3. GAITHERSBURG, Md., July 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced it plans to report second quarter financial results and provide a corporate update on Monday, August 9, 2021, via press release, after market close.

    The press release will be accessible under the investor section of the NexImmune's website at www.neximmune.com.

    About NexImmune

    NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent, and durable…

    GAITHERSBURG, Md., July 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced it plans to report second quarter financial results and provide a corporate update on Monday, August 9, 2021, via press release, after market close.

    The press release will be accessible under the investor section of the NexImmune's website at www.neximmune.com.

    About NexImmune

    NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune's approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.

    NexImmune's two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to at least 3 prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.

    For more information, visit www.neximmune.com.

    Forward Looking Statements

    This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NexImmune, Inc. (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning our planned and ongoing clinical studies for the Company's product candidates, including NEXI-001 and NEXI-002; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the utility of prior preclinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission ("SEC") on March 31, 2021, and subsequent reports that we file with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    Contacts

    Investors:

    Chad Rubin, SVP Corporate Affairs

    NexImmune, Inc.

    646.319.3261

    crubin@neximmune.com



    Primary Logo

    View Full Article Hide Full Article
    • Dr. Jack A. Ragheb as Senior Vice President, Translational Science
    • Matt Schiller, Head of Business Development

    GAITHERSBURG, Md., July 14, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Jack A. Ragheb, MD, PhD, has been appointed to the newly created position of Senior Vice President, Translational Science, bringing more than 30 years of experience in translational and clinical research in the fields of cell therapy, gene therapy, immunology and virology. In addition, Matt Schiller has been appointed to Head of Business Development…

    • Dr. Jack A. Ragheb as Senior Vice President, Translational Science
    • Matt Schiller, Head of Business Development

    GAITHERSBURG, Md., July 14, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Jack A. Ragheb, MD, PhD, has been appointed to the newly created position of Senior Vice President, Translational Science, bringing more than 30 years of experience in translational and clinical research in the fields of cell therapy, gene therapy, immunology and virology. In addition, Matt Schiller has been appointed to Head of Business Development, bringing more than 20 years of business development experience across developmental stage life science companies and large pharma.

    "We are excited to announce the continued expansion of our leadership team," said Scott Carmer, Chief Executive Officer of NexImmune. "Jack brings decades of relevant experience that span the fields of translational science and clinical research. He joins us at a critical point as we advance the work needed to translate the pre-clinical potential of our proprietary AIM-nanoparticle technology platform into clinical development programs across the cancer, infectious disease and auto-immune disease areas. His expertise and insight will help inform and drive much of this work."

    "Matt has a proven track record in global pharmaceutical and biotech business development. As a small and growing company, we will be looking for both academic and strategic partnerships to help us efficiently advance and expand our technology platform into areas both within and outside of our current focus on cancer. We are thrilled to have Matt join us in a role that's responsible for leading these important efforts to fruition," continued Mr. Carmer.

    Dr. Ragheb was most recently a Senior Medical Fellow for Immunology and Co-chair of the Immunogenicity/Immunosafety Working group at Eli Lilly. Prior to his time at Eli Lilly, Dr. Ragheb was a Chief Medical Research Officer in the Office of Biological Products with the Center for Drug Evaluation and Research at the U.S. FDA. He was previously a Senior Clinical Investigator at the National Eye Institute, NIH and an Attending Physician on the Allergy-Immunology Service of the National Institute of Allergy and Infectious Disease (NIAID), NIH. Dr. Ragheb trained at Johns Hopkins University, obtaining both an M.D. and Ph.D. in Genetics.  He is a Diplomate of the American Board of Allergy and Immunology.

    "I'm humbled and excited to join the highly accomplished team at NexImmune and look forward to contributing to the advancement of its preclinical pipeline and clinical assets," said Dr. Ragheb.

    Mr. Schiller has over 20 years of experience in business development, global licensing and commercial development. Most recently, Mr. Schiller served as Director, Global Licensing & Business Development, Immunology at EMD Serono, a business of Merck KGaA. Prior to his time at EMD Serono, Mr. Schiller served as Head of Licensing at Cell Signaling Technology, VP of Business Development at Ensemble Discovery and Senior Director of Business Development at Critical Therapeutics. Mr. Schiller holds a BS in Chemistry from the University of South Florida.

    "NexImmune's ability to direct T Cells may create significantly better outcomes for people with chronic and life-threatening diseases," said Mr. Schiller. "I look forward to enabling partnerships that will help bring this exciting technology to patients."

    About NexImmune

    NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune's approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.

    NexImmune's two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to at least 3 prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.

    For more information, visit www.neximmune.com.

    Forward Looking Statements

    This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NexImmune, Inc. (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning our planned and ongoing clinical studies for the Company's product candidates, including NEXI-001 and NEXI-002; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the utility of prior preclinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission ("SEC") on March 31, 2021, and subsequent reports that we file with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    Contacts

    Investors:

    Chad Rubin, SVP Corporate Affairs

    NexImmune, Inc.

    646.319.3261

     crubin@neximmune.com

    Media:

    Mike Beyer

    Sam Brown Inc. Healthcare Communications

    312.961.2502

    mikebeyer@sambrown.com



    Primary Logo

    View Full Article Hide Full Article
View All NexImmune Inc. News